Analytical Protein Microarrays: Advancements Towards Clinical Applications.
Analytical Protein Microarrays: Advancements Towards Clinical Applications.
复制标题
DOI：
10.3390/s17020256
复制
发表时间：
2017-01-29
期刊：
影响因子：
--
通讯作者：
Sauer U
中科院分区：
文献类型：
--
作者：
Sauer U
蛋白质微阵列代表着一种强大的技术，具有在诊断、药物开发、食品安全和环境监测等众多应用中作为检测广泛分析物的工具的潜力。分析蛋白质微阵列的主要特点包括高通量和由于试剂消耗最少而成本相对较低、多路复用、快速动力学和测量，以及功能集成的可能性。到目前为止，特别是分子和细胞生物学的基础研究已经使用蛋白质微阵列进行，而临床应用的潜力，特别是医疗保健点应用还没有充分利用。问题是，为了充分利用这项技术，必须实现哪些功能，必须进行哪些改进。在过去，为了在诊断领域推广蛋白质微阵列技术，我们已经确定了必须克服的各种障碍。例如，需要显著改进以使这项技术对诊断市场更具吸引力的问题包括：灵敏度太低且重复性不足、分析时间不足、缺乏高质量的抗体和有效试剂、缺乏自动化和便携式仪器，以及芯片生产和读出所需仪器的成本。手头这份文件的范围是审查解决这些问题的方法。
Protein microarrays represent a powerful technology with the potential to serve as tools for the detection of a broad range of analytes in numerous applications such as diagnostics, drug development, food safety, and environmental monitoring. Key features of analytical protein microarrays include high throughput and relatively low costs due to minimal reagent consumption, multiplexing, fast kinetics and hence measurements, and the possibility of functional integration. So far, especially fundamental studies in molecular and cell biology have been conducted using protein microarrays, while the potential for clinical, notably point-of-care applications is not yet fully utilized. The question arises what features have to be implemented and what improvements have to be made in order to fully exploit the technology. In the past we have identified various obstacles that have to be overcome in order to promote protein microarray technology in the diagnostic field. Issues that need significant improvement to make the technology more attractive for the diagnostic market are for instance: too low sensitivity and deficiency in reproducibility, inadequate analysis time, lack of high-quality antibodies and validated reagents, lack of automation and portable instruments, and cost of instruments necessary for chip production and read-out. The scope of the paper at hand is to review approaches to solve these problems.